HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AP23236

Src tyrosine kinase inhibitor; structure in first source

Also Known As:

AP-23236

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenols: 677
        AP23236: 2
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - AP23236: 2

Experts

1.	Rucci, Nadia: 1 article (04/2008)
2.	Susa, Maria: 1 article (04/2008)
3.	Teti, Anna: 1 article (04/2008)
4.	Bohacek, Regine S: 1 article (09/2003)
5.	Dalgarno, David C: 1 article (09/2003)
6.	Keenan, Terence: 1 article (09/2003)
7.	Metcalf, Chester A: 1 article (09/2003)
8.	Sawyer, Tomi K: 1 article (09/2003)
9.	Shakespeare, William C: 1 article (09/2003)
10.	Sundaramoorthi, Raji: 1 article (09/2003)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 09/01/2003 - "In summary, AP-22408 and AP-23236, which differ mechanistically by virtue of blocking Src-dependent non-catalytic or catalytic activities in osteoclasts, exemplify ARIAD Pharmaceuticals' structure-based design of novel bone-targeted lead compounds, successfully achieving in vivo proof-of-concept and providing the framework for the next-generation molecules that have further advanced, in terms of preclinical studies, for the treatment of osteoporosis and related bone diseases, including osteolytic bone metastases." 04/01/2008 - "The purine-based c-Src inhibitor AP23451 and the dual c-Src/Abl inhibitors AP22408 and AP23236 proved efficacious in reducing bone metastases in preclinical studies. "
2.	Osteoporosis 09/01/2003 - "In summary, AP-22408 and AP-23236, which differ mechanistically by virtue of blocking Src-dependent non-catalytic or catalytic activities in osteoclasts, exemplify ARIAD Pharmaceuticals' structure-based design of novel bone-targeted lead compounds, successfully achieving in vivo proof-of-concept and providing the framework for the next-generation molecules that have further advanced, in terms of preclinical studies, for the treatment of osteoporosis and related bone diseases, including osteolytic bone metastases."
3.	Bone Diseases (Bone Disease) 09/01/2003 - "In summary, AP-22408 and AP-23236, which differ mechanistically by virtue of blocking Src-dependent non-catalytic or catalytic activities in osteoclasts, exemplify ARIAD Pharmaceuticals' structure-based design of novel bone-targeted lead compounds, successfully achieving in vivo proof-of-concept and providing the framework for the next-generation molecules that have further advanced, in terms of preclinical studies, for the treatment of osteoporosis and related bone diseases, including osteolytic bone metastases."

Related Drugs and Biologics

1.	AP 23451
2.	AP22408
3.	purine